• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

    8/8/23 4:05:00 PM ET
    $LH
    $OMIC
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $LH alert in real time by email

    SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology.

    "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to welcome her to the Board of Directors," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "Her extensive experience in applying new technologies to impact precision medicine at scale complements our mission to innovate next-generation sequencing and multiomics platforms that empower researchers and clinicians."

    Since 2014, Dr. Eisenberg has served as Chief Scientific Officer of Labcorp Diagnostics and more recently was appointed as Labcorp's Enterprise Chief Scientific Officer. She served in a variety of other roles at Labcorp and its affiliates starting in 1990. Dr. Eisenberg has extensive experience with forensic DNA testing, biotechnology, molecular genetics, and molecular oncology. She has helped lead the development and validation of well over a thousand clinical assays used for patient care during her more than 30-year tenure at Labcorp. Dr. Eisenberg previously held roles on the National Institute of Environmental Health Sciences and the Federal Bureau of Investigation's DNA Advisory Board, where she was later recognized for her contributions to the advancement of DNA technology. A molecular biologist by training, Dr. Eisenberg was a member of the team responsible for commercializing polymerase chain reaction (PCR) tests in the 1990s, making large-scale testing possible. Dr. Eisenberg has been recognized multiple times in her career including as a Healthcare Businesswomen's Association Luminary in 2021, as one of Fierce Healthcare's 2021 Women of Influence, and as one of the Fierce Healthcare's Fiercest Women in Life Sciences in 2022. Dr. Eisenberg received her B.S. degree in Biology and her B.A. degree in Psychology from the State University of New York at Albany, her M.S. degree in Molecular Biology from the State University of New York at Albany, and her Ph.D. in Molecular Biology from the University of Kentucky.

    "I have been impressed by Singular Genomics' growth and progress in launching a sequencing platform that I believe is uniquely positioned to positively impact many critical applications," said Dr. Eisenberg. "Drew and the rest of the leadership team have the strategic vision, collaborative spirit, and underlying technology needed to succeed and lead in the next-generation sequencing and multiomics space, and I am proud to contribute as a board member."

    About Singular Genomics Systems, Inc.

    Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular's proprietary sequencing technology, applying it as an in situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics' mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.

    Forward-Looking Statements

    Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include and are not limited to quotes from management and statements regarding our ability to successfully manufacture and commercialize the G4 in accordance with our timelines, objectives, and specifications. Any such forward-looking statements are based on our management's current expectations and are subject to risks and uncertainties that could cause our actual future results to differ materially from our management's current expectations or those implied by our forward-looking statements. These risks and uncertainties include and are not limited to our limited history of manufacturing and commercializing our products or technology, and the risk factors described in more detail in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. Accordingly, you should not rely on forward-looking statements as predictions of future events or our future performance. Except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.

    Investor Contact

    Matt Clawson

    949-370-8500

    [email protected]

    Media Contact

    Dan Budwick, 1AB

    973-271-6085

    [email protected]



    Primary Logo

    Get the next $LH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LH
    $OMIC

    CompanyDatePrice TargetRatingAnalyst
    Labcorp Holdings Inc.
    $LH
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    Labcorp Holdings Inc.
    $LH
    4/2/2025$276.00Buy
    Redburn Atlantic
    Labcorp Holdings Inc.
    $LH
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    Labcorp Holdings Inc.
    $LH
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    Labcorp Holdings Inc.
    $LH
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    Labcorp Holdings Inc.
    $LH
    10/30/2024Hold → Buy
    HSBC Securities
    Labcorp Holdings Inc.
    $LH
    10/1/2024$235.00Neutral
    Piper Sandler
    Labcorp Holdings Inc.
    $LH
    3/25/2024$250.00Hold → Buy
    Argus
    More analyst ratings

    $LH
    $OMIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

      7/10/25 9:03:30 AM ET
      $LH
      Medical Specialities
      Health Care
    • Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

      Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

      4/2/25 8:50:29 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. upgraded by Citigroup with a new price target

      Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

      3/4/25 7:36:42 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    $OMIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tang Kevin bought $1,806,220 worth of shares (122,416 units at $14.75) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      9/18/24 4:31:08 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Spaventa Andrew bought $49,612 worth of shares (118,468 units at $0.42) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:31:38 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Glezer Eli N. bought $85,640 worth of shares (200,000 units at $0.43), increasing direct ownership by 5% to 4,570,000 units (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:30:55 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LH
    $OMIC
    SEC Filings

    See more
    • Labcorp Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

      7/24/25 6:52:21 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

      7/10/25 6:58:16 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

      6/27/25 4:16:25 PM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    $OMIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Kerrii B sold $132,500 worth of shares (500 units at $265.00), decreasing direct ownership by 4% to 12,166 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      7/2/25 10:37:22 AM ET
      $LH
      Medical Specialities
      Health Care
    • Director Anderson Kerrii B sold $130,000 worth of shares (500 units at $260.00), decreasing direct ownership by 4% to 12,666 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      6/12/25 10:07:20 AM ET
      $LH
      Medical Specialities
      Health Care
    • EVP, Pres of ED, CMO & CSO Caveney Brian J sold $494,000 worth of shares (2,000 units at $247.00), decreasing direct ownership by 6% to 30,067 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      6/5/25 8:19:38 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    $OMIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

      SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/22/24 7:55:51 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D filed by Singular Genomics Systems Inc.

      SC 13D - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/5/24 7:29:21 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

      SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/1/24 7:54:29 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LH
    $OMIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

      ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

      7/8/25 9:00:00 AM ET
      $LH
      $PRVA
      Medical Specialities
      Health Care
      Medical/Nursing Services
    • SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

      SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv

      5/12/25 9:00:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

      Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

      11/19/24 7:00:00 AM ET
      $BGNE
      $LH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities

    $LH
    $OMIC
    Financials

    Live finance-specific insights

    See more
    • Labcorp Announces 2025 Second Quarter Results

      Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024:Revenue: $3.53 billion versus $3.22 billionDiluted EPS: $2.84 versus $2.43Adjusted EPS: $4.35 versus $3.94Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis pointsAdjusted EPS range narrowed to $16.05 to $16.50; midpoint raised by $0.23Free Cash Flow range of $1.13 billion to $1.28 billion; midpoint raised by $25 millionBroadened our partnerships with hospitals, health systems and regional/local labs and enhanced access to comprehensive testing and laboratory servicesIntroduced several new tests

      7/24/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Declares Quarterly Dividend

      BURLINGTON, N.C., July 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2025, to stockholders of record as of the close of business on August 28, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and

      7/10/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp to Announce Second Quarter Financial Results on July 24, 2025

      BURLINGTON, N.C., June 26, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2025 before the market opens on Thursday, July 24, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan

      6/26/25 4:10:00 PM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    $OMIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Announces 2025 Second Quarter Results

      Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024:Revenue: $3.53 billion versus $3.22 billionDiluted EPS: $2.84 versus $2.43Adjusted EPS: $4.35 versus $3.94Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis pointsAdjusted EPS range narrowed to $16.05 to $16.50; midpoint raised by $0.23Free Cash Flow range of $1.13 billion to $1.28 billion; midpoint raised by $25 millionBroadened our partnerships with hospitals, health systems and regional/local labs and enhanced access to comprehensive testing and laboratory servicesIntroduced several new tests

      7/24/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Community Health Systems Announces Definitive Agreement to Sell Select Outreach Laboratory Assets to Labcorp

      Agreement aims to provide broader access to testing and laboratory services to communities across the U.S. Community Health Systems, Inc. (Company) (NYSE:CYH) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has entered into a definitive agreement with Labcorp (NYSE:LH), pursuant to which Labcorp will acquire select assets and assume certain leases of the ambulatory outreach laboratory services of CHS health systems in 13 states, including certain patient service centers and in-office phlebotomy locations, for $195 million cash. When the transaction is complete, CHS patients and providers will benefit from broader access to Labcorp's comprehensive testing a

      7/22/25 4:15:00 PM ET
      $CYH
      $LH
      Hospital/Nursing Management
      Health Care
      Medical Specialities
    • Labcorp Declares Quarterly Dividend

      BURLINGTON, N.C., July 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2025, to stockholders of record as of the close of business on August 28, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and

      7/10/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care